Jan 16, 2024 · The multicenter, double-blind, randomized, placebo-controlled Phase 2 trial will evaluate the efficacy and safety of ilofotase alfa as a ...
Missing: Farma | Show results with:Farma
OUR MISSION. AM-Pharma strives to develop medicines for patients confronted with severe medical conditions. Our proprietary asset, ilofotase alfa, is being ...
People also ask
Who is the CEO of AM Pharma?
What is recAP AM Pharma?
Mar 9, 2018 · CEO at AgomAb Therapeutics ... It is with great pleasure to announce that recAP significantly reduced mortality in our phase IIb study. We must ...
Missing: Farma | Show results with:Farma
The nomination is based on AM-Pharma's two-part adaptive Phase II clinical trial design of recAP in patients with sepsis-associated Acute Kidney Injury.
Missing: Farma | Show results with:Farma
Oct 20, 2022 · Ilofotase alfa failed to improve kidney function in the first seven days, causing the phase 2 to miss its primary endpoint and Pfizer to walk ...
Missing: Farma | Show results with:Farma
Sep 26, 2023 · The planned double-blind, randomized, placebo-controlled Phase 2 clinical trial will evaluate the safety and efficacy of ilofotase alfa in 150 ...
Missing: Farma | Show results with:Farma
Jan 16, 2024 · Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery.
AM-Pharma is a Dutch biopharmaceutical company developing a biotherapeutic for the treatment of Sepsis Associated Acute Kidney Injury (SA-AKI). The company ...
Missing: Farma | Show results with:Farma
The STOP-AKI adaptive Phase II trial is being conducted in two parts. ... About AM-Pharma www.am‐pharma.com. AM‐Pharma is a biopharmaceutical ...
No information is available for this page. · Learn why